Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133189 | 1.00 | PRCP (0.37) | PRCPHTR1ASLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL52335 | 0.98 | PRCP (0.36) | PRCPHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11072585 | 0.85 | PRCP (0.43) | PRCPHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3869434 | 0.85 | PRCP (0.43) | PRCPHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31569538 | 0.80 | PRCP (0.47) | PRCPHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9600234 | 0.72 | PRCP (0.57) | PRCPCHRNB2CHRNA4 | |
| SCHEMBL31374588 | 0.72 | PRCP (0.57) | PRCPCHRNB2CHRNA4 | |
| SCHEMBL31374586 | 0.72 | PRCP (0.57) | PRCPCHRNB2CHRNA4 | |
| SCHEMBL25732308 | 0.69 | CYP19A1 (0.36) | SLC6A4CYP19A1DRD2DRD1 | |
| SCHEMBL10152945 | 0.67 | HTR1A (0.42) | HTR1ASLC6A2SLC6A4SLC6A3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076011-A1 | Enantiomer-Pure Hexahydro-Pyrrolocyclopenta-Pyridine Derivatives | BINDER, EVA (AT) | 2010-03-25 | — | — | US | disclosed |
| EP-1740585-B1 | ENANTIOMER-PURE HEXAHYDROPYRROLOCYCLOPENTAPYRIDINE DERIVATIVES | BINDER EVA (AT) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076011-A1 | Enantiomer-Pure Hexahydro-Pyrrolocyclopenta-Pyridine Derivatives | FFAR3, FFAR2, FFAR1 | PRCP 2159/4885HTR1A 361/4885SLC6A2 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.